Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Endorses Teikoku’s Donepezil Tape for Alzheimer’s and More Drugs
November 28, 2022
- LDP Lawmakers’ League Holds Hearing on SaMD Review Status
November 28, 2022
- Japan to Begin Xocova Supply on Nov. 28 ahead of Schedule
November 28, 2022
- MHLW Panel OKs 111 More Health Damage Claims for COVID-19 Vaccines
November 28, 2022
- Japan Approves Label Expansion for Enhertu, TS-1, and More
November 25, 2022
- Upper House Health Committee OKs Bill to Amend Infectious Disease Act
November 25, 2022
- LDP Pharma Study Group Calls for Careful Discussions on Off-Year Plan: Proposal
November 25, 2022
- LDP Lawmakers’ League Boots Up for Medical Adhesive Patches
November 24, 2022
- LDP League Urges MEXT to Provide Accurate Info on HPV Vaccines at Medical Schools
November 24, 2022
- MOF Panel Proposal Expected to Spell Out Full Annual Price Revision
November 24, 2022
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
- Defense Buildup Won’t Impact Degree of Cuts in Social Security Costs: MHLW Official
November 22, 2022
- Bill to Amend Intractable Disease Law Passes Lower House
November 22, 2022
- Enough Antipyretic Analgesic Agents Secured for Twindemic, MHLW Says
November 21, 2022
- LDP Tax Council to Compile FY2023 Reform Proposal by Mid-December
November 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
- Chuikyo Reps Tussle over Product Coverage Threshold for Off-Year Price Revision
November 17, 2022
- Evrenzo to Add Hypothyroidism Risk in Label Revision
November 17, 2022
- MHLW Unveils Overview of Genome Analysis Project Organ for FY2025 Launch
November 17, 2022
- MHLW to Run Health Survey for COVID-19 Vaccination in Children
November 16, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…